Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) investors are having a rough day following the news that deaths observed in non-human primate toxicology studies put the company’s ARC-520 program, …
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) and Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH) announced an agreement to perform collaborative studies on Arrowhead’s ARC-520 and Spring Bank’s …
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) shares are up nearly 6% as of this writing, after the RNAi therapeutics company announced a collaboration with Amgen (NASDAQ:AMGN) …
In a research report issued yesterday, Cantor analyst Elemer Piros reiterated a Buy rating on shares of Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR), with a price …
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) announced that it has dosed the first patient in the multiple ascending dose (MAD) portion of its ongoing Phase 1/2 …
This morning, Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) announced the initiation of its Phase II trial for its pipeline drug ARC-AAT, a RNAi based investigational …
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) announced that it initiated a Phase 2 clinical study of ARC-AAT, an investigational RNAi-based medicine for the treatment of liver …
Arrowhead on the cutting edge of providing curative hepatitis B, says Cantor analyst
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) announced financial results for its fiscal 2016 third quarter ended June 30, 2016. Fiscal 2016 Third Quarter and Recent …
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) announced that it initiated a Phase 1/2 study of ARC-521, the company’s second RNAi-based investigational medicine for the treatment of …
